ClinicalTrials.govpublic full text
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
ovarian neoplasms, ovarian cancer, niraparib, gsk3985771, poly(adenosine diphosphate [adp]-ribose) polymerase (parp)inhibitor, homologous recombination deficiency (hrd), hrd positive, prima, prima clinical trial, prima study, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1031265
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.